Navigation Links
Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
Date:7/21/2008

e inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such expressed or implied forward looking statements could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertaint
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Lorus Therapeutics Receives $600 Thousand From Escrow Account
2. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
3. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
4. Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
7. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
8. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
9. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
10. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
11. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 /PRNewswire-iReach/ -- Tute ... interpretation, today announced an agreement with Lineagen, ... for Lineagen,s NextStep Dx PLUS.  Lineagen, ... and neurological disorders, currently offers FirstStep Dx ... testing service used by healthcare providers as ...
(Date:7/10/2014)... THOUSAND OAKS, Calif., July 10, 2014   Ceres, ... biotechnology and seed company, announced today financial results for ... an update on its business. Ceres reported ... progress in product performance this growing season in Brazil, ... that affected the company,s sorghum evaluation areas for part ...
(Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
(Date:7/10/2014)... A new study published today in the journal ... has found that time of day and sleep deprivation ... could be crucial when looking at the best time ... and heart disease, and for administering medicines effectively. , ... of Cancer Research, London, investigated the links between sleep ...
Breaking Biology Technology:Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2Time of day crucial to accurately test for diseases, new research finds 2
... Radio frequency identification technology is often touted as a way ... world, the technology is bringing other, perhaps more important benefits: ... supply chain now, and there are tremendous applications in health ... the marketplace," said Reik Read, an analyst with Robert ...
... Madison, Wis. Wisconsin's research and development funding has exceeded expectations, reaching ... had set a target of $3.3 billion by 2005. , ... R&D spending per capita, and 13 th in academic R&D ... match the growth rate in R&D the last few years," said ...
... - TEKLYNX International a developer of ... (AIDC) marketplace, has announced LABELVIEW 8 label design and ... code label printing. , ,The updates enhance label ... greatly extend Pocket LABELVIEW printer support to over 1,000 ...
Cached Biology Technology:RFID can be a matter of life and death in the medical world 2RFID can be a matter of life and death in the medical world 3RFID can be a matter of life and death in the medical world 4RFID can be a matter of life and death in the medical world 5New report says Wisconsin R&D spending exceeding expectations 2
(Date:7/11/2014)... transplantation of mesenchymal stem cells can stimulate neurogenesis in ... Alzheimer,s disease (AD) and improve tissue and function injury ... reported on the therapeutic effect of adipose-derived stem cells ... effect on oxidative injury and neurogenesis in the brain ... School of Life Sciences, Tsinghua University, China transplanted ADSCs ...
(Date:7/11/2014)... hippocampus, the marginal division of the striatum is ... the impact degree of substance P in the ... Yan Yu and his team, College of Biophotonics, ... staining, that substance P receptor, neurokinin 1 was ... division of normal rats. Unilateral or bilateral injection ...
(Date:7/11/2014)... the normal circumstances, astrocytes participate in normal ... and exhibit therapeutic and repairing effects on ... have found that nerve cells differentiated from ... reduced viability, which produces influences on subsequent ... General Hospital, Hebei United University, China demonstrated ...
Breaking Biology News(10 mins):
... 2011 With millions of people warding off winter,s ... raising red flags about the potential health effects of ... in the American Chemical Society,s (ACS,) journal, Chemical ... inhaled into the lungs from wood smoke may have ...
... Darwin, the "tree of life" has been the preeminent metaphor ... changing of individual species. The discovery that a large ... species of fungus to another, however, significantly strengthens the argument ... more appropriate. "The fungi are telling us something important ...
... reports that family mealtimes that contain three ingredients in the ... who have chronic asthma. "Family mealtimes, when they,re done ... reduced risk of substance abuse, eating disorders, and obesity. In ... we can see minute by minute which factors deliver these ...
Cached Biology News:Discovery of jumping gene cluster tangles tree of life 2Discovery of jumping gene cluster tangles tree of life 3Recipe for family mealtimes calls for 3 ingredients in the right amounts 2
MOUSE ANTI HUMAN CYTOKERATIN 1-8...
Immunogen: Tissue / cell preparation. (Murine EHS laminin preparation) Storage: -20 C, Avoid Freeze/Thaw Cycles...
p-Raf-1 (Ser 338/Tyr 341)-R...
Rabbit polyclonal to Syntrophin alpha 1 ( Abpromise for all tested applications). entrezGeneID: 6640 SwissProtID: Q13424...
Biology Products: